BioPharma

Olympic champion and Australian icon Cathy Freeman will be the guest of honour at tonight's 2026 Patient’s Choice Awards, a national celebration of the people and organisations helping to make healthcare more compassionate, responsive and centred on the needs of patients.

Chief executive and co-founder Sally Panton said the Mitsubishi partnership was an important vote of confidence in the company’s ambitions to build a regulated cellular-health platform with international reach.

Noxopharm says new laboratory findings strengthen the case for using its Sofra technology to help the immune system recognise cancer cells after treatments such as chemotherapy or radiotherapy kill them.

Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division.

Entropy Neurodynamics has signed an agreement with the University of California, San Francisco, to develop a US Phase 2 trial comparing its intravenous psilocin treatment TRP-8803 with the widely used antidepressant escitalopram in young adults with major depressive disorder.

Neuren Pharmaceuticals has announced it will begin paying dividends to shareholders for the first time after a sharp increase in royalty income from the Rett syndrome treatment DAYBUE (trofinetide).

Chief executive Cheryl Maley said the year brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships, and further validation of DEP technology's potential in targeted cancer treatment.

Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome profiling and create a larger ASX-listed diagnostics business.

Any assessment of Australia’s use of health technology assessment requires an historical lens, at the very least for context, but also for learnings. The system's history makes it predictable. It is how we know what comes next.

Chief executive Jon Pilcher said the approval was especially meaningful given the lack of an approved Rett syndrome treatment in Europe to date.

QIMR Berghofer, one of Australia's leading medical research institutions, has appointed internationally recognised geneticist Professor Brandon Wainwright AM as its next Director and Chief Executive Officer.

Dr Krishan Thiru, Medical Director for Pfizer Australia and New Zealand, said the results provide important local evidence at a time when infants face their greatest risk of severe RSV disease.